MNG891
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.309
- PANCREAS_BETA_CELLS+0.295
- SPERMATOGENESIS+0.268
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.224
- HEDGEHOG_SIGNALING+0.208
- APICAL_SURFACE+0.193
- MITOTIC_SPINDLE+0.170
- E2F_TARGETS+0.096
- MYOGENESIS+0.091
- XENOBIOTIC_METABOLISM+0.071
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.443
- INTERFERON_GAMMA_RESPONSE-0.379
- TNFA_SIGNALING_VIA_NFKB-0.331
- MYC_TARGETS_V1-0.291
- MYC_TARGETS_V2-0.291
- TGF_BETA_SIGNALING-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.259
- ALLOGRAFT_REJECTION-0.248
- ANDROGEN_RESPONSE-0.234
- DNA_REPAIR-0.229
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG854 | — | — | 0.856 |
| 2 | MNG35 | — | — | 0.791 |
| 3 | MNG686 | — | — | 0.776 |
| 4 | SRR12202490 | — | — | 0.765 |
| 5 | ERR4976610 | — | E | 0.752 |
| 6 | SRR1797259 | — | cohortSC | 0.748 |
| 7 | TCGA-ZF-A9RC-01A-11R-A38B-07 | — | — | 0.744 |
| 8 | TCGA-FD-A5BV-01A-11R-A26T-07 | — | — | 0.739 |
| 9 | SRR1516070 | — | — | 0.736 |
| 10 | SRR12696783 | — | — | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.309 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.295 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.268 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.224 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.208 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.193 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.096 | Inavolisib | — uncovered |
| MYOGENESIS | 0.091 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.071 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.066 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.065 | Inavolisib | — uncovered |
| COAGULATION | 0.064 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.035 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.025 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.014 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.009 | Inavolisib | — uncovered |